Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04896359
Other study ID # HUBI - 14539
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 15, 2019
Est. completion date March 3, 2021

Study information

Verified date September 2021
Source Universidad San Francisco de Quito
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, randomize, double-blind, and placebo-controlled study to evaluate in patients with clinical criteria for any of the following open surgical procedure: (1) cesarean section; (2) aesthetic surgery like abdominoplasty; (3) orthopedic surgery; and (4) abdominal open surgery [excluding laparoscopic procedures] will be invited to receive either a high dose of vitamin C (12.5 g) three times (48 h pre-surgery, immediately before surgery and 48 h post-surgery) or its placebo, to evaluate the tissue repair process using an international validated instrument named Patient and Observer Scar Assessment Scale.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date March 3, 2021
Est. primary completion date March 3, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Older than 18 years. - Susceptible for any of the following surgical procedures: (1) cesarean section; (2) aesthetic abdominal plastic surgery; (3) orthopedic prosthetic replacement surgery - Voluntary consent to participate Exclusion Criteria: - Known allergy to the vitamin C - Known problems with wounds healing - Kidney disease (including lithiasis) or gout

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Vitamin C
12.5 grams of ascorbic acid
Other:
Placebo
vehicle

Locations

Country Name City State
Ecuador Hospital de los Valles Quito Pichincha

Sponsors (2)

Lead Sponsor Collaborator
Universidad San Francisco de Quito Biomolec Pharma

Country where clinical trial is conducted

Ecuador, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of linear scars Patient and Observer Scar Assessment Scale (it evaluates in a 0 to 10 scale: vascularity, pigmentation, thickness, relief, pliability and surface area) initial assessment, two weeks after surgery
Primary Evaluation of linear scars Patient and Observer Scar Assessment Scale (it evaluates in a 0 to 10 scale: vascularity, pigmentation, thickness, relief, pliability and surface area) second assessment, one month after surgery
Primary Evaluation of linear scars Patient and Observer Scar Assessment Scale (it evaluates in a 0 to 10 scale: vascularity, pigmentation, thickness, relief, pliability and surface area) third assessment, three months after surgery
See also
  Status Clinical Trial Phase
Completed NCT03040921 - Uterine Transposition: Feasibility Study N/A
Completed NCT04389047 - Comparison of Two Mechanical Ventilation Modes on Oxygenisation
Enrolling by invitation NCT03123458 - Clonal Fetal Mesenchymal Stem Cells (cfMSCs) for the Control of Immune-related Disorders Phase 1